Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.87 · Revenue $15.00M · 1 analysts
Est. EPS $-1.55 · Revenue $1.00M · 1 analysts
Est. EPS $-4.58 · Revenue $34.37M · 2 analysts
Est. EPS $-1.69 · Revenue $3.00M · 1 analysts
EPS $-4.48 · Revenue $18.62M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $18.6M | — | -84.7% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-76.7M | — | -21.4% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +100.0% | — | -10.7% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -412.6% | — | -755.5% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -411.9% | — | -693.3% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-42.6M | — | +88.1% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -228.7% | — | +22.1% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 1.8% | — | -31.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 6.53x | — | -33.0% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $278.4M | — | -4.1% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -4.48 vs -4.57 | +1.9% | -1.18 vs -1.42 | +16.8% |
| Revenue Surprise | $18.6M vs $21.0M | -11.5% | $3.0M vs $666667 | +350.6% |
| Name | Title | Gender | Year Born | Status |
|---|---|---|---|---|
Husam Younis | Chief Scientific Officer | — | 1974 | Active |
Brendan Winslow | Chief Financial Officer | Male | 1988 | Active |
Steven George Hughes | Chief Medical Officer | — | 1967 | Active |
Kathleen Gallagher | President, CEO & Director | Female | 1981 | Active |
Rocio Martin Hoyos | Chief Strategy Officer | Female | 1983 | Active |
Stephanie Kenney | Chief Corporate Affairs Officer | Female | 1978 | Active |
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it will participate in upcoming investor conferences in September.
SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on August 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company. The employee received, in the aggregate, non-qualified stock options to purchase 11,000 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $13.48 per share, the closing price of the Company's common stock as reported by Nasdaq on the grant date, 25% of which will vest and become exercisable on the first anniversary of the grant date, and the remainder of which will vest in 36 substantially equal installments each month thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 5,500 shares of the Company's common stock, 25% of which will vest on the first anniversary of the grant date, and the remainder of which will vest in 3 substantially equal installments each year thereafter, subject to the employee's continued service with the Company through each applicable vesting date (collectively, the "Awards").
-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress including FDA clearance of its Investigational New Drug (IND) application for ATR 1072 and continued achievements under its collaboration with Bristol Myers Squibb (BMS). "Our team continues to execute well, achieving FDA clearance of our IND for ATR 1072 and launching Corventis — Atrium's first Phase 1/2 trial and the first clinical study to evaluate a potential disease-modifying treatment for people living with PRKAG2 syndrome," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics.
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's ongoing collaboration. "Atrium's vision is to deliver treatments that address the underlying cause of serious heart disease, including rare genetic cardiomyopathies," said Kathleen Gallagher, President and CEO of Atrium Therapeutics.
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.
